# US 2012/0083492 A1 · Imidazopyrazines for use as kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083492 A1
- Document ID: US20120083492A1
- Status: Published application
- Kind: A1
- Application number: 13/264,544
- Filed: 2010-04-16
- Published: 2012-04-05
- Earliest claimed: 2009-04-16
- Assignees: Centro Nacional de Investigaciones Oncologicas (CNIO)
- Inventors: Joaquin Pastor Fernández; Sonia Martínez Gonzalez; Julen Oyarzabal Santamarina
- Web page: https://patentgrep.com/patent/US20120083492A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided compounds of formula (I), wherein R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

## Claims

### Claim 1

A compound of formula I,
wherein:
R1 represents:
(a) —N(R1a)R1b,
in which R1a and R1b are linked together to form, together with the nitrogen atom to which they are necessarily attached, a 5- to 7-membered ring optionally containing a further one or two heteroatoms, optionally containing one or two double bonds, and which ring is optionally substituted by one or more substituents selected from ═O and B1;
(b) a heterocycloalkyl group (attached to the requisite imidazopyrazine via a carbon atom), optionally substituted by one or more substituents selected from ═O and B2;
(c) a monocyclic heteroaryl group optionally substituted by one or more substituents selected from B3;
R2 and R3 independently represent:
(i) hydrogen;
(ii) Q1;
(iii) C1-12 alkyl optionally substituted by one or more substituents selected from ═O, ═S, ═N(R10a) and Q2; or
R2 or R3 may represent a fragment of formula IA,
m represents 0, 1, 2, 3, 4, 5 or 6;
each R15 represents hydrogen, halo or C1-6 alkyl optionally substituted by one or more substituents selected from E1; or
the two R15 groups may linked together to form (along with the requisite carbon atom to which those R15 groups are necessarily attached) a 3- to 6-membered (spiro-cyclic) ring, which ring optionally contains one or more double bonds, and optionally contains a further heteroatom selected from nitrogen, sulfur and oxygen, and which ring is optionally substituted by one or more substituents selected from E2;
Ra and Rb are linked together, along with the requisite nitrogen atom to which they are necessarily attached, to form a first 3- to 7-membered cyclic group, optionally containing one further heteroatom selected from nitrogen, sulfur and oxygen, and which ring:
(a) is fused to a second ring that is either a 3- to 7-membered saturated heterocycloalkyl group containing one to four heteroatoms selected from oxygen, sulfur and nitrogen, a 3- to 12-membered saturated carbocyclic ring, or an unsaturated 5- to 12-membered carbocyclic or heterocyclic ring;
(b) comprises a linker group —(C(Rx)2)p— and/or —(C(Rx)2)r—O—(C(Rx)2)s— (wherein p is 1 or 2; r is 0 or 1; s is 0 or 1; and each Rx independently represents hydrogen or C1-6 alkyl), linking together any two non-adjacent atoms of the first 3- to 7-membered ring (i.e. forming a bridged structure); or
(c) comprises a second ring that is either a 3- to 12-membered saturated carbocyclic ring or a 3- to 7-membered saturated heterocycloalkyl group containing one to four heteroatoms selected from oxygen and nitrogen, and which second ring is linked together with the first ring via a single carbon atom common to both rings (i.e. forming a spiro-cycle),
all of which cyclic groups, defined by the linkage of Ra and Rb, are optionally substituted by one or more substituents selected from ═O and E3;
R4 represents hydrogen or a substituent selected from halo, —CN, —OR10b, —N(R10b)R11b, —C(O)N(R10b)R11b, —C(O)R10b), C1-6 alkyl and heterocycloalkyl, which latter two groups are optionally substituted by one or more substituents selected from E4 and ═O;
but wherein at least one of R2, R3 and R4 represents a substituent other than hydrogen;
R5 represents aryl or heteroaryl (both of which are optionally substituted by one or more substituents selected from E5);
each Q1 and Q2 independently represents, on each occasion when used herein:
halo, —CN, —NO2, —N(R10a)R11a, —OR10a, —C(═Y)—R10a, —C(═Y)—OR10a, —C(═Y)N(R10a)R11a, —OC(═Y)—R10a, —OC(═Y)—OR10a, —OC(═Y)—OR10a, —OC(═Y)N(R10a)R11a, —OS(O)2OR10a, —OP(═Y)(OR10a)(OR11a), —OP(OR10a)(OR11a), —N(R12a)C(═Y)R11a, —N(R12a)C(═Y)OR11a, —N(R12a)C(═Y)N(R10a)R11a, —NR12aaS(O)2R10a, —NR12aS(O)2N(R10a)R11a, —S(O)2N(R10a)R11a, —SC(═Y)R10a, —S(O)2R10a, —SR10a, —S(O)R10a, C1-12 alkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from ═O, ═S, ═N(R10a) and E6), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from E7);
each B1, B2 and B3 independently represent halo, —NO2, —CN, —N(R10a)R11a, —OR10a, —C(═Y)—R10a, —C(═Y)—OR10a, —C(═Y)N(R10a)R11a, —N(R12a)C(═Y)R11a, —N(R12a)C(═Y)OR11a, —N(R12a)C(═Y)N(R10a)R11a, —NR12aS(O)2R10a; —NR12aS(O)2N(R10a)R11a, —S(O)2N(R10a)R11a, —SC(═Y)R10a, —SC(═Y)OR10a, —S(O)2R10a, C1-12 alkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from ═O and E8), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from E9);
or, any two B1 substituents, when attached to the same carbon atom (thereby forming a spiro-cycle), may be linked together to form, a 3- to 12-membered ring, optionally containing one or more heteroatoms, which ring optionally contains one or more double bonds, and which ring is itself optionally substituted by one or more substituents selected from halo, ═O and C1-3 alkyl optionally substituted by one or more fluoro atoms;
each R10a, R11a, R12a, R10b and R11b independently represent, on each occasion when used herein, hydrogen, C1-12 alkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from ═O, ═S, ═N(R20) and E10), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from E11); or
any relevant pair of R10a, R11a and R12a and/or any pair of R10b and R11b may be linked together to form a 3- to 20-membered ring, optionally containing one or more heteroatoms, optionally containing one or more unsaturations, and which ring is optionally substituted by one or more substituents selected from ═O, ═S, ═N(R20) and E12;
each E1, E2, E3, E4, E5, E6, E7, E8, E9, E10, E11 and E12 independently represents, on each occasion when used herein:
(i) Q4;
(ii) C1-12 alkyl optionally substituted by one or more substituents selected from ═O and
Q5; or
any two E1, E2, E3, E4, E5, E6, E7, E8, E9, E10, E11 or E12 groups may be linked together to form a 3- to 12-membered ring, optionally containing one or more unsaturations, and which ring is optionally substituted by one or more substituents selected from ═O and J1;
each Q4 and Q5 independently represent, on each occasion when used herein:
halo, —CN, —NO2, —N(R20)R21, —OR20, —C(═Y)—R20, —C(═Y)—OR20, —C(═Y)N(R20)R21, —OC(═Y)—R20, —OC(═Y)—OR20, —OC(═Y)N(R20)R21, —OS(O)2OR20, —OP(═Y)(OR20)(OR21), —OP(OR20)(OR21), —N(R22)C(═Y)R21, —N(R22)C(═Y)OR21, —N(R22)C(═Y)N(R20)R21, —NR22S(O)2R20, —NR22S(O)2N(R20)R21, —S(O)2N(R20)R21, —SC(═Y)R20, —S(O)2R20, —SR20, —S(O)R20, C1-6 alkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from ═O and J2), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from J3);
each Y independently represents, on each occasion when used herein, ═O, ═S, ═NR23 or ═N—CN;
each R20, R21, R22 and R23 independently represent, on each occasion when used herein, hydrogen, C1-6 alkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or more substituents selected from J4 and ═O), aryl or heteroaryl (which latter two groups are optionally substituted by one or more substituents selected from J5); or
any relevant pair of R20, R21 and R22, may be linked together to form a 3- to 20-membered ring, optionally containing one or more heteroatoms, optionally containing one or more unsaturations, and which ring is optionally substituted by one or more substituents selected from J6 and ═O;
each J1, J2, J3, J4, J5 and J6 independently represents, on each occasion when used herein:
(i) Q7;
(ii) C1-6 alkyl or heterocycloalkyl, both of which are optionally substituted by one or more substituents selected from ═O and Q8;
each Q7 and Q8 independently represents, on each occasion when used herein:
—CN, halo, —N(R50)R51, —OR50, —C(═Ya)—R50, —C(═Ya)—OR50, —C(═Ya)N(R50)R51, —N(R52)C(═Ya)R51, —NR52S(O)2R50, —S(O)2R50, —SR50, —S(O)R50 or C1-6 alkyl optionally substituted by one or more fluoro atoms;
each Ya independently represents, on each occasion when used herein, ═O, ═S, ═NR53 or ═N—CN;
each R50, R51, R52 and R53 independently represents, on each occasion when used herein, hydrogen or C1-6 alkyl optionally substituted by one or more substituents selected from fluoro, —OR60 and —N(R61)R62; or
any relevant pair of R50, R51 and R52 may be linked together to form, a 3- to 8-membered ring, optionally containing one or more heteroatoms, optionally containing one or more unsaturations, and which ring is optionally substituted by one or more substituents selected from ═O and C1-3 alkyl;
R60, R61 and R62 independently represent hydrogen or C1-6 alkyl optionally substituted by one or more fluoro atoms;
or a pharmaceutically acceptable ester, amide, solvate or salt thereof.

### Claim 2 (depends on 1)

A compound as claimed in claim 1 wherein:
R4 represents hydrogen or a substituent selected from halo, —CN, —OR10b, —N(R10b)R11b, —C(O)N(R10b)R11b, C1-6 alkyl and heterocycloalkyl, which latter two groups are optionally substituted by one or more substituents selected from E4 and ═O; and
each Q7 and Q8 independently represents, on each occasion when used herein halo, —N(R50)R51, —OR50, —C(═Ya)—R50, —C(═Ya)—OR50, —C(═Ya)N(R50)R51, —N(R52)C(═Ya)R51, —NR52S(O)2R50, —S(O)2R50, —SR50, —S(O)R50 or C1-6 alkyl optionally substituted by one or more fluoro atoms.

### Claim 3 (depends on 1)

A compound as claimed in claim 1, wherein: R1 represents —N(R1a)R1b, in which R1a and R1b are linked together to form a 6-membered ring containing a further oxygen heteroatom (so forming a morpholinyl group), which ring may be unsubstituted, or may be substituted by one or more B1 groups (such groups are preferably unsubstituted); R2 and R3 independently represent(s) hydrogen or a substituent selected from halo (e.g. bromo, chloro, iodo) —CN, —N(R10a)R11a, —C(═Y)OR10a, —C(═Y)—R10a, —C(═Y)—N(R10a)R11a, C1-6 alkyl (optionally substituted by one or more (e.g. one) substituent(s) selected from E6) and heterocycloalkyl (e.g. a 5- or, preferably, a 6-membered heterocycloalkyl group, which preferably contains one heteroatom (e.g. nitrogen), and which may contain one unsaturation, e.g a double bond, so forming e.g. a piperidinyl ring, e.g. 4-piperidinyl, for example in which the 1,2-position optionally contains a double bond), which heterocycloalkyl group is optionally substituted by one or more substituents selected from ═O and, preferably, E6 (e.g. in which the E6 substituent is located on a nitrogen heteroatom); R4 represents hydrogen, chloro, bromo, iodo or —CN; R5 represents aryl (e.g. phenyl) or heteroaryl (e.g. a 5- or preferably a 6-membered monocyclic heteroaryl group, or a 10- or, preferably, 9-membered bicyclic heteroaryl group, in which, in both cases, there is one or two heteroatom(s) present, preferably selected from nitrogen, so forming e.g. pyridyl, indazolyl, indolyl, pyrimidinyl, indolonyl or pyrrolopyridine, such as pyrrolo[2,3]pyridine), both of which R5 groups are optionally substituted by one or more (e.g. one or two) substituents selected from E5; each R10a, R11a, R12a, R10b and R11b (e.g. each R10a and R11a) independently represents hydrogen or C1-6 (e.g. C1-4) alkyl optionally substituted by one or more substituents selected from ═O and E10; or any relevant pair of R10a, R11a, and R12a (e.g. R10a and R11a) may (e.g. when both are attached to the same nitrogen atom) be linked together to form a 4- to 8-membered ring, optionally containing a further heteroatom, and optionally substituted by one or more substituents selected from ═O and E12; and/or each E1, E2, E3, E4, E5, E6, E7, E8, E9, E10, E11 and E12 (independently represents C1-12 alkyl optionally substituted by one or more substituents selected from ═O and Q5, or, preferably (each E1 to E12 independently represent) Q4.

### Claim 4 (depends on 1)

A compound as claimed in claim 1, wherein each Q4 and Q5 (e.g. each Q4) independently represent halo, —N(R20)R21, —OR20, —C(═Y)—OR20, —C(═Y)N(R20)R21, —N(R22)C(═Y)R21, —N(R22)C(═Y)N(R20)R21, —NR22S(O)2R20, —S(O)2R20 and/or C1-6 alkyl (optionally substituted by one or more substituents selected from ═O and J2); and/or each R20, R21, R22 and R23 (e.g. each R20 and R21) independently represents hydrogen or C1-6 (e.g. C1-4) alkyl optionally substituted by one or more substituents selected from ═O and J4; or any relevant pair of R20, R21 and R22 (e.g. R20 and R21) may (e.g. when both are attached to the same nitrogen atom) may be linked together to form a 4- to 8-membered ring, optionally containing a further heteroatom, and optionally substituted by one or more substituents selected from ═O and J6.

### Claim 5 (depends on 1)

A compound as claimed in claim 1, wherein: each J1, J2, J3, J4, J5 and J6 independently represent C1-6 (e.g. C1-3) alkyl optionally substituted by one or more substituents selected from Q8, or, J1 to J6 more preferably represent a substituent selected from Q7; each Q7 and Q8 independently represent halo, —N(R50)R51, —OR50, —C(═Ya)—OR50, —C(═Ya)—R50, —S(O)2R50 or C1-3 alkyl optionally substituted by one or more fluoro atoms; each R50, R51, R52 and R53 independently represents hydrogen or C1-6 (e.g. C14) alkyl optionally substituted by one or more fluoro atoms; and/or each R60, R61 and R62 independently represents hydrogen or C1-2 alkyl (e.g. methyl).

### Claim 6

(canceled)

### Claim 7 (depends on 1)

A pharmaceutical formulation comprising a compound of claim 1, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

### Claim at position 8

8-9. (canceled)

### Claim 10 (depends on 11)

A method according to claim 11, wherein the disease is cancer, an immune disorder, a cardiovascular disease, a viral infection, inflammation, a metabolism/endocrine function disorder, a neurological disorder, an obstructive airways disease, an allergic disease, an inflammatory disease, immunosuppression, a disorder commonly connected with organ transplantation, an AIDS-related disease, benign prostate hyperplasia, familial adenomatosis, polyposis, neuro-fibromatosis, psoriasis, a bone disorder, atherosclerosis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis, restenosis, stroke, diabetes, hepatomegaly, Alzheimer's disease, cystic fibrosis, a hormone-related disease, an immunodeficiency disorder, a destructive bone disorder, an infectious disease, a condition associated with cell death, thrombin-induced platelet aggregation, chronic myelogenous leukaemia, liver disease, a pathologic immune condition involving T cell activation, CNS disorders, and other associated diseases.

### Claim 11 (depends on 1)

A method of treatment of a disease in which inhibition of a PI3-K and/or mTOR is desired and/or required, which method comprises administration of a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically-acceptable ester, amide, solvate or salt thereof, to a patient suffering from, or susceptible to, such a condition.

### Claim 12 (depends on 1)

A combination product comprising:
(A) a compound according to claim 1, or a pharmaceutically-acceptable ester, amide, solvate or salt thereof; and
(B) another therapeutic agent that is useful in the treatment of in the treatment of cancer and/or a proliferative disease,
wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.

### Claim 13 (depends on 1)

A process for the preparation of a compound of formula I as defined in claim 1, which process comprises:
(i) reaction of a compound of formula I, which comprises reaction of a compound of formula IB,
wherein L1 represents a suitable leaving group, and R1, R2, R3, and R4 are as defined in claim 1, with a compound of formula IC,
R5-L2 IC
wherein L2 represents a suitable group, and R5 is as defined in claim 1;
(ii) reaction of a compound of formula ID,
wherein L3 represents a suitable leaving group, and R2, R3, R4 and R5 are as defined in claim 1, with a compound of formula IE,
R1-L4 IE
wherein L4 represents a suitable leaving group, and R1 is as defined in claim 1; (iii) reaction of a compound of formula IF,
wherein R1 and R4 are as defined in claim 1, and L1 is as defined above, with a compound of formula IG,
R2—C(O)—C(R3)(H)-L5 IG
wherein L5 represents a suitable leaving group, and R2 and R3 are as defined in claim 1, followed by reaction with a compound of formula IC as defined above;
(iv) reaction of a compound of formula IF as defined above but in which L1 is replaced with a R5 group (and R5 is as defined in claim 1), with a compound of formula IH,
R3—C(H)(L6a)-C(H)(L6b)-R3 IH
wherein L6a and L6b independently represent a suitable leaving group, and each R3 is as defined in claim 1;
(v) for compounds of formula I in which R3 or R4 represents bromo, iodo or chloro, reaction of a corresponding compound of formula I, in which R3 or R4 (as appropriate) represents hydrogen, with a reagent that is a source of halide ions;
(vi) for compounds of formula I in which R3 or R4 represents a substituent other that hydrogen, or halo (e.g. bromo, iodo or chloro), reaction of a corresponding compound of formula I, in which R3 or R4 (as appropriate) represents bromo, chloro or iodo, with a compound of formula IJ,
R3/4-L7 IJ
wherein R3/4 represents R3 or R4 (as appropriate), and L7 represents a suitable leaving group.

### Claim 14 (depends on 1)

A process for the preparation of a pharmaceutical formulation comprising a compound of claim 1, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, which process comprises bringing into association a compound of claim 1, or a pharmaceutically acceptable ester, amide, solvate or salt thereof with a pharmaceutically-acceptable adjuvant, diluent or carrier.

### Claim 15 (depends on 1)

A process for the preparation of a combination product comprising:
(A) a compound according to claim 1 but without the provisos, or a pharmaceutically-acceptable ester, amide, solvate or salt thereof; and
(B) another therapeutic agent that is useful in the treatment of in the treatment of cancer and/or a proliferative disease,
wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier,
which process comprises bringing into association a compound according to claim 1 but without the provisos, or a pharmaceutically acceptable ester, amide, solvate or salt thereof with the other therapeutic agent that is useful in the treatment of cancer and/or a proliferative disease, and at least one pharmaceutically-acceptable adjuvant, diluent or carrier.
